Abstracts tagged "Behcet’s syndrome"

Abstract Number: 2729 • 2017 ACR/ARHP Annual Meeting
Surgical Therapies in the Treatment of Pulmonary Artery Involvement in Behcet’s Syndrome
Hasan Tuzun¹, Gul Guzelant², Ozkan Demirhan³, Buge Oz⁴, Izzet Fresko², Vedat Hamuryudan², Hasan Yazici² and Emire Seyahi², ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Cardiovascular Surgery, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³Istanbul Bilim University, Medical Faculty, Department of Thoracic Surgery, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical Faculty, Department of Pathology, Istanbul, Turkey
Background/Purpose: The mainstay treatment of pulmonary artery involvement (PAI) in Behcet’s syndrome (BS) is immunosuppresion and corticosteroids (1). The role of surgical intervention in the…
Abstract Number: 2732 • 2017 ACR/ARHP Annual Meeting
Recommendations for the Management of Neuro-Behcet’s Disease By the Japanese National Research Committee for Behcet’s Disease
Hirotoshi Kikuchi¹, Tetsuji Sawada², Masato Okada³, Mitsuhiro Takeno⁴, Masataka Kuwana⁴, Yoshiaki Ishigatsubo⁵, Izumi Kawachi⁶, Hideki Mochizuki⁷, Susumu Kusunoki⁸ and Shunsei Hirohata⁹, ¹Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan, ²Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, ³Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, ⁴Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁶Department of Neurology, Niigata University Medical and Dental Hospital, Niigata, Japan, ⁷Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan, ⁸Department of Neurology, Kinki University School of Medicine, Osaka, Japan, ⁹Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Central nervous system involvement is one of the most serious complications in Behçet’s disease (BD). This condition is referred to as neuro-Behçet’s disease (NB)…
Abstract Number: 2744 • 2017 ACR/ARHP Annual Meeting
Long-Term Remission in Severe Behcet’s Disease Following Withdrawal of Successful Anti-TNF Treatment
Petros P Sfikakis¹, Aikaterini Arida¹, Stylianos Panopoulos², Kalliopi Fragkiadaki², George Pentazos³, Katerina Laskari³, Maria Tektonidou¹ and Nikos Markomichelakis², ¹First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, athens, Greece, ²First Department of Propaedeutic and Internal Medicine and Joint Rheumatology Program, National and Kapodistrian University of Athens Medical School, Athens, Greece, ³Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece
Background/Purpose: Anti-TNF treatment has been shown to be effective in inducing complete remission in many Behcet’s disease (BD) patients with eye, large vessel, intestine and…
Abstract Number: 2747 • 2017 ACR/ARHP Annual Meeting
Long Term Follow-up of Behcet’s Syndrome Patients Treated with Cyclophosphamide
Mert Gurcan¹, Sinem Nihal Esatoglu¹, Vedat Hamuryudan¹, Caner Saygin², Didem Saygin³, Serdal Ugurlu⁴, Emire Seyahi¹, Melike Melikoglu¹, Izzet Fresko¹, Sebahattin Yurdakul¹, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Department of Hematology and Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Cleveland, OH, ³Internal Medicine, Department of Internal Medicine, Cleveland Clinic, Cleveland, Cleveland, OH, ⁴Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Cyclophosphamide (CYC) remains an important treatment option for Behçet’s syndrome (BS) pts with life threatening conditions such as arterial aneurysms. However, several adverse events…
Abstract Number: 2748 • 2017 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Among Patients with Behcet’s Syndrome: A Controlled Study
Sinem Nihal Esatoglu¹, Fatma Nihan Akkoc¹, Yesim Ozguler¹, Fatma Ozbakir², Okan Kadir Nohut², Dilsen Cevirgen³, Vedat Hamuryudan¹, Ibrahim Hatemi⁴, Aykut Ferhat Celik⁵, Hasan Yazici¹ and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Central Research Laboratory, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of and Rheumatology, Istanbul, Turkey, ⁴Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Immunogenicity of anti-TNFs has been recognized as an important problem that may cause loss of response and adverse events such as infusion reactions. We…
Abstract Number: 77 • 2017 ACR/ARHP Annual Meeting
Platelets Induce IL-1b Production in Human Monocytes through NLRP3 Inflammasome Activation
Shota Nakano¹, Hiroki Mitoma¹, Shotaro Kawano¹, Shoichiro Inokuchi², Masahiro Ayano¹, Yasutaka Kimoto³, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horiuchi⁴ and Hiroaki Niro⁵, ¹Department of Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, ²Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
Background/Purpose: Recent studies have revealed that platelets play pivotal roles in inflammation in addition to hemostasis. The thrombus induces subsequent local inflammation and reversely the…
Abstract Number: 2775 • 2017 ACR/ARHP Annual Meeting
Critical Role of Neutrophil Extracellular Traps (NETs) in Patients with Behcet’s Disease
Alexandre LE JONCOUR^1,2, Stephane Loyau³, Nicolas Lelay⁴, Marie-Christine Bouton⁵, Antoine Dossier⁶, Anne-Claire Desbois⁷, Fanny Domont⁸, Thomas Papo⁹, Martine Jandrot-Perrus⁵, Patrice Cacoub¹⁰, Nadine Ajzenberg⁵, David saadoun⁷ and Yacine Boulaftali², ¹Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie (DHU i2B), F-75005, Paris, France., National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France, ²INSERM 1148, CHU Xavier Bichat, paris, France, ³Unité INSERM 1148, CHU Xavier Bichat, Faris, France, ⁴2. Unité INSERM 1148, CHU Xavier Bichat, paris, France, ⁵Unité INSERM 1148, CHU Xavier Bichat, paris, France, ⁶3. Service de Médecine Interne, CHU Xavier Bichat, paris, France, ⁷Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France, ⁸Département Hospitalo-Universitaire Inflammation-Immunopathologie-Biotherapie, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, paris, France, ⁹Service de Médecine Interne, CHU Xavier Bichat, Paris, France, ¹⁰Département de Médecine Interne et Immunologie Clinique, National center for Autoimmune and Systemic rare diseases and for Autoinflammatory diseases, Paris, France
Background/Purpose: Behçet's disease (BD) is a chronic systemic vasculitis characterised by muco-cutaneous, ocular, gastrointestinal, cerebral recurrent lesions. Venous thrombosis, is a frequent and life-threatening complication.…
Abstract Number: 1075 • 2017 ACR/ARHP Annual Meeting
Higher Frequencies of Lymphocytes Expressing the Natural Killer Group 2D Receptor and Cytotoxic Potential of NK Cells in Patients with Behcet Disease
Martina Bonacini¹, Stefania Croci¹, Alessandra Soriano^2,3, Eleonora Calò¹, Alessandro Zerbini¹, Luca Cimino⁴, Francesco Muratore^2,5, Luigi Fontana⁶, Maria Parmeggiani¹ and Carlo Salvarani^2,5, ¹Unit of Clinical Immunology, Allergy and Advanced Biotechnologies, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ²Unit of Rheumatology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ³Campus Bio-Medico, University of Rome, Italy, Roma, Italy, ⁴Unit of Ocular Immunology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy, ⁵University of Modena and Reggio Emilia, Italy, Modena, Italy, ⁶Unit of Ophthalmology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia, Italy, Reggio Emilia, Italy
Background/Purpose: Behçhet disease (BD) is a rare, systemic, inflammatory disorder with multiorgan damage and various clinical manifestations such as oral ulcers, genital ulcers and uveitis.…
Abstract Number: 108 • 2017 Pediatric Rheumatology Symposium
Characteristics and long-term outcome of children and adolescents with initial diagnosis of Behçet’s disease in a tertiary care center in Brazil
Milagro Raquel Tovar-Avila¹, Francisco Hugo Gomes², Lucenir Da Silva³, Virginia Ferriani⁴ and Luciana Carvalho², ¹Pediatric Reumatology Division, Ribeirão Preto Medical School - University of São Paulo, Rbeirão Preto, Brazil, ²Pediatric Rheumatology Division, Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, Brazil, ³Rheumatology Division, Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, Brazil, ⁴Pediatric Reumatology Division, Ribeirão Preto Medical School - University of São Paulo, Ribeirão Preto, Brazil
Background/Purpose: Behet's disease (BD) is a rare systemic inflammatory disease with nonspecific clinical presentation that can mimic infections, tumors and other diseases. Diagnostic delay of…
Abstract Number: 109 • 2017 Pediatric Rheumatology Symposium
Clinical features of pediatric Behçet’s disease patients in Japan
Ken-ichi Yamaguchi¹ and Satoshi Fujikawa², ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Immuno－Rheumatology Center, St.luke's International Hospital, Tokyo, Japan
Background/Purpose: To diagnose pediatric patients as Behçet’s disease (BD) is challenging. Sensitivity of four BD criteria, three BD criteria made for adult patients and Paediatric…
Abstract Number: 2941 • 2016 ACR/ARHP Annual Meeting
Optimization of Adalimumab on Refractory Uveitis of Behcet’s Syndrome. Multicenter Study of 23 Patients
Carlos Fernández-Díaz¹, Ricardo Blanco¹, Vanesa Calvo-Río¹, Javier Loricera¹, J. Sanchez-bursón², Norberto Ortego Centeno³, Jose L. García Serrano⁴, Miguel Cordero⁵, J. Vazquez⁶, Emma Beltran⁷, Elia Valls⁸, O. Maiz Alonso⁹, Ana Blanco¹⁰, Ignacio Torre¹¹, Angel García-Aparicio¹², F.j Toyos-saénz¹³, L. Martinez-Costa¹⁴, Lucia C. Domínguez-Casas¹, Natalia Palmou¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology, Hospital Valme, Hospital Valme, Sevilla, Spain, ³Medicine Department, Hospital Universitario San Cecilio, Granada, Spain, ⁴Ophthalmology, Hospital Universitario San Cecilio, Granada, Spain, ⁵Ophthalmology, Hospital de León, León, Spain, ⁶Rheumatology, Hospital de Ferrol, Ferrol, Spain, ⁷Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁸Rheumatology, Hospital Dr. Peset., Valencia, Spain, ⁹Rheumatology, Hospital Donostia, San Sebastian, Spain, ¹⁰Ophthalmology Department. Donostia University Hospital, Donostia, Spain, ¹¹Rheumatology, Hospital de Basurto, Bilbao, Spain, ¹²Rheumatology, Ophthalmology and rheumatology, Hospital de Ferrol, Ferrol, Ferrol, Spain, ¹³Rheumatology,, Hospital Virgen de la Macarena, Sevilla, Spain, ¹⁴Hospital Dr. Peset., Valencia, Spain
Background/Purpose: In non-infectious no anterior uveitis, adalimumab (ADA) is the only biologic drug that has shown efficacy in phase III randomized, double blind studies,…
Abstract Number: 2945 • 2016 ACR/ARHP Annual Meeting
Systematic Review: “Efficacy and Safety of Biological Versus Immunosuppressive Therapy Compared to Placebo in the Treatment of Uveitis Associated with BehçEt’s Disease.”
Ana Urruticoechea-Arana¹, Tatiana Cobo-Ibáñez², Virginia Villaverde García³, Montserrat Santos-Gómez⁴, Kelly Vargas Osorio⁵, Federico Díaz-González⁶, Leslie Fariñas Padrón⁵, Vanesa Calvo-Río⁷ and Ricardo Blanco Alonso⁷, ¹Hospital Can Misses, Ibiza, Spain, ²Hospital Universitario Reina Sofía, Universidad Europea de Madrid, Madrid, Spain, ³Rheumatology, Hospital Universitario de Móstoles, Móstoles, Spain, ⁴Rheumatology, Hospital Can Misses, Ibiza, Spain, ⁵Family and Community Medicine, Hospital Can Misses, Ibiza, Spain, ⁶Rheumatology, Hospital Universitario de Canarias, S/C Tenerife, Spain, ⁷Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose:
Abstract Number: 2947 • 2016 ACR/ARHP Annual Meeting
Adalimumab Versus Infliximab in Cystoid Macular Edema of Uveitis Associated to BehçEt Disease. Multicenter Study of 34 Patients
Lucia Cristina Domínguez-Casas¹, Vanesa Calvo-Río¹, Ricardo Blanco², Carlos Fernández-Díaz¹, Paz Rodríguez-Cundín³, Emma Beltran⁴, Marisa Hernández-Garfella⁵, Jose M Herreras⁶, Miguel Cordero-Coma⁷, Marina Mesquida⁸, Alfredo Adan⁹, M. Victoria Hernández¹⁰, David Diaz-Valle¹¹, Ignacio Torre-Salaberri¹², Manuel Díaz-Llopis¹³, Roberto Gallego¹⁴, Olga Maiz-Alonso¹⁵, Santos Insua¹⁶, Félix Francisco¹⁷, Raquel Almodóvar González¹⁸, Oscar Ruiz Moreno¹⁹, Fernando Jiménez-Zorzo²⁰, Javier Manero²¹, Myriam Gandía²², Joan Miquel Nolla²³, Nuria Vegas-Revenga²⁴, Natalia Palmou-Fontana¹ and Miguel Angel Gonzalez-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ²Rheumatology Department. Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Preventive Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ⁴Rheumatology, Hospital General Universitario de Valencia, Valencia, Spain, ⁵Ophtamology, Hospital General Universitario de Valencia, Valencia, Spain, ⁶Ophthalmology, Hospital Universitario, IOBA, Valladolid, Spain, ⁷Ophthalmology, Hospital de León, León, Spain, ⁸Ophthalmology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁹Ophthalmology, Hospital Clinic de Barcelona,, Barcelona, Spain, ¹⁰Rheumatology, Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ¹¹Ophthalmology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹²Rheumatology, Hospital de Basurto, Bilbao, Spain, ¹³Hospital Universitario La Fe, Valencia, Spain, ¹⁴Ophtalmology, Hospital Universitario La Fe, Valencia, Spain, ¹⁵Hospital Universitario Donostia, Donostia, Spain, ¹⁶Rheumatology, Hospital Universitario Santiago de Compostela, La Coruña, Spain, ¹⁷Rheumatology, Hospital Doctor Negrín, Las Palmas de Gran Canaria, Spain, ¹⁸Rheumatology Unit, Hospital Universitario Fundación Alcorcón, Madrid, Spain, ¹⁹Ophthalmology and Rheumatology., Hospital Miguel Servet, Zaragoza, Spain, ²⁰Hospital Miguel Servet, Zaragoza, Spain, ²¹Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, ²²Rheumatology, Hospital Puerta del Mar, Cadiz, Spain, ²³Rheumatology, Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁴Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain
Background/Purpose: Cystoid macular edema (CME) is the most serious complication of uveitis and the most common cause of blindness in uveitis. Our aim was…
Abstract Number: 2948 • 2016 ACR/ARHP Annual Meeting
Fecal Calprotectin Level Is Useful in Identifying Active Disease in Behçet’s Syndrome Patients with Gastrointestinal Involvement: A Controlled Study
Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Yesim Ozguler³, Gulen Hatemi³, Hafize Uzun⁴, Aykut Ferhat Celik⁵ and Hasan Yazici³, ¹Rheumatology, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical School, Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁴Biochemistry, Istanbul University, Cerrahpasa Medical School, Department of Biochemistry, Istanbul, Turkey, ⁵Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: The fecal calprotectin (FC) is widely used as a non-invasive method for identifying patients with active Crohn’s disease (CD) and ulcerative colitis. Gastrointestinal involvement…
Abstract Number: 2949 • 2016 ACR/ARHP Annual Meeting
Surgical Method for Aortic Root Involvement of Behcet Disease
Byeongzu Ghang¹, Suk Jung Choo², Oh Chan Kwon³, Seokchan Hong⁴, Yong-Gil Kim⁵, Chang-Keun Lee⁵ and Bin Yoo⁵, ¹Division of Rheumatology, Department of Internal Medicine, Univerisy of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ²Division of Thoracic and Cardiovascular Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, The Republic of, ³Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea, The Republic of, ⁴Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Department of Rheumatology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: Aortic regurgitation (AR) in Behcet disease is a rare but very fatal condition. Many patients require a second or third operation after simple aortic…

« Previous Page
1
…
3
4
5
6
7
…
12
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].